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Abstract
Objective:  To  deduce  recommendations  from  the  literature  on  the  management  of  kidney  dam-
age caused  by  tuberous  sclerosis  complex  (TSC).
Material  and  methods:  Five  practitioners  have  written  up  recommendations  after  reviewing  the
literature.  They  were  evaluated  by  14  experts  using  a  9  level  scale  (1:  complete  disagreement;
9: complete  agreement),  then  reworded  until  each  item  received  a  median  score  of  greater
than or  equal  to  8.
Results:  Forty-eight  to  80%  of  patients  with  TSC  have  kidney  disease  with  the  presence  of
angiomyolipomas  (AML),  cysts,  cancers  and/or  progression  towards  renal  insufﬁciency.  An
abdominal  ultrasound  (and  serum  creatinine  level  if  there  is  an  abnormality)  is  recommended  as
soon as  the  TSC  is  diagnosed.  The  evaluation  should  be  repeated  every  3  to  5  years  if  it  is  normal.
Numerous  and  voluminous  cysts  are  suggestive  of  associated  polycystosis.  After  20  years  of  age,
the monitoring  should  be  based  on  CT  scan  or  MRI,  which  are  more  precise  in  the  monitoring  of
AML. The  biopsy  of  a  renal  mass  should  be  discussed  if  there  are  calciﬁcations,  central  necrosis
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or  rapid  growth.  Lymphangioleiomyomatosis  should  be  screened  for  in  women  via  pulmonary  CT
scan at  18  and  30  to  40  years  of  age.  Haemorrhagic  rupture  of  an  AML  should  be  treated  in  ﬁrst-
line by  embolisation.  Asymptomatic  AMLs  that  cumulate  risk  factors  for  bleeding  (size  >  80  mm,
predominant  vascular  contingent,  micro-aneurisms)  should  be  preventively  treated,  if  possible
by embolisation.  The  role  of  mTOR  inhibitors  remains  to  be  deﬁned.
Conclusion:  Monitoring  and  a  standardised  treatment  are  necessary  to  improve  the  treatment
of renal  damage  caused  by  TSC.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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[uberous  sclerosis  complex  (TSC)  is  a  autosomal  dominant
hakomatosis  affecting  approximately  one  in  6000  births,
ith  a  prevalence  of  one  in  11,000  to  14,000  after  the  age
f  10  years  [1,2]. It  is  caused  by  damage  to  the  TSC1  (9q34)
r  TSC2  (16p13)  genes  coding  respectively  for  hamartin  and
uberin,  which  regulate  cell  proliferation  and  the  mTOR
oute.  TSC  is  characterised  by  the  growth  of  multiple  hamar-
omatous  lesions  (brain,  skin,  kidneys,  heart,  lungs,  retina,
tc.).  The  neurological  signs  are  predominant  with  epilepsy,
ental  retardation  and/or  behavioural  disorders  such  as
utism  [1,3].
Kidney  damage  is  the  second  cause  of  mortal-
ty/morbidity  all  ages  combined  and  the  ﬁrst  cause  of
ortality  after  30  years  of  age  [4—7]. It  affects  48  to  80%
f  patients  [5,8—11], and  is  dominated  by  the  onset  of
ngiomyolipomas  (AMLs),  cortical  cysts,  malignant  lesions
r  lesions  with  malignant  potential  (renal  cell  carcinomas,
pithelioid  angiomyolipomas  [EAMLs])  and/or  chronic  renal
nsufﬁciency  (CRI).
Renal  AMLs  affect  34  to  80%  of  patients  [8—10,12,13].
hey  are  numerous,  bilateral  and  voluminous  [14—17], espe-
ially  if  there  is  mutation  of  TSC2  [10,13]  or  intellectual
etardation  [13,18].  Patients  with  AML  appear  to  have  more
ommon  retinal  hamartomas,  cardiac  rhabdomyomas  and
utaneous  lesions  [4].  The  main  complication  of  AML  is
pontaneous  haemorrhagic  rupture,  which  can  require  a
ephrectomy  or  emergency  embolisation.  AMLs  can  also
estroy  the  renal  parenchyma  and  create  CRI  [16,19].
Renal  cysts  affect  14  to  45%  of  adults  with  TSC  and  10
o  20%  of  children  [5,8,10,12,20].  Small  and  rarely  symp-
omatic  [10,21],  their  number  is  less  than  5  in  45  to  64%  of
ases.  They  are  bilateral  in  22  to  60%  of  cases  [10,20].
The  progression  towards  CRI,  which  is  a  cause  of  death
n  adulthood  [7],  concerns  less  than  2  to  5%  of  patients
21—23].  It  can  be  iatrogenic  (nephrectomy,  embolisations,
rug  toxicity),  or  caused  by  AMLs  or  renal  polycystosis  (RPC)
9,19,20,24].  The  TSC2  gene  is  the  neighbour  of  the  PKD1
ene  (16p13.3)  involved  in  adult  dominant  RPC.  A  deletion
hat  simultaneously  affects  both  genes  can  give  rise  to  RPC
hat  can  be  detected  starting  in  childhood  and  causes  ter-
inal  CRI  in  the  second  or  third  decade  of  life  (‘‘TSC2/PKD1
ontiguous  gene  syndrome’’)  [3,5,25].
The  association  between  TSC  and  malignant  kidney
umours  remains  a  subject  of  debate  [26], with  a  cancer
ate  of  0.5  to  4.2%  [5,8,10].  Paediatric  cases  and  multiple
umours  [27,28]  have  given  rise  to  the  hypothesis  that  TSC
ould  be  a  risk  factor,  but  this  remains  controversial  [26].
ertain  cancers  described  could  also  correspond  to  EAMLs,
 potentially  malignant  variant  of  AMLs  [6,29—34].The  management  of  renal  damage  caused  by  TSC,  which
s  potentially  serious,  is  still  not  very  standardised.  The
bjective  of  this  work  is  to  summarise  this  renal  damage
nd  deduce  recommendations  for  management  from  the  lit-
rature.
aterial and methods
n  September  2008,  the  French  Reference  Centre  on  TSC
alled  on  the  Urology,  Nephrology  and  Imaging  Departments
f  French  University  Hospital  Centres  (UHCs)  to  establish
ecommendations  on  the  treatment  of  renal  damage  caused
y  TSC.  In  May  2009,  the  physicians  who  were  interested  in
ine  UHCs  wrote  up  10  practical  questions  that  should  be
he  object  of  recommendations.  Five  practitioners  (OR,  HN,
Z,  NG,  ELC)  wrote  up,  after  reviewing  the  literature,  a  ﬁrst
ersion  of  the  recommendations,  which  was  evaluated  by
 panel  of  experts.  The  agreement  of  the  experts  for  each
tem  was  estimated  using  a  Likert  scale  with  nine  levels  (1:
omplete  disagreement;  9:  complete  agreement)  and  free
omments.  The  recommendations  were  reworded  until  each
tem  received  a  median  score  of  greater  than  or  equal  to
.
linical questions and recommendations
hould kidney damage caused by tuberous
clerosis complex be screened for?
he  objective  of  screening  for  kidney  damage  caused  by
SC  is  the  prevention  of  the  progressive  risks  (death,
leeding,  CRI,  cancer).  Its  beneﬁt  on  the  incidence  of
omplications  and  morbidity/mortality  has  not  been  stud-
ed.  However,  a  renal  evaluation  should  be  a  part  of
he  initial  treatment  of  patients  for  most  of  the  authors
1,4,9,20,24,35,36].
RECOMMENDATION  1:  NEED  FOR  SCREENING  FOR
KIDNEY  DAMAGE
Due  to  their  frequency  and  severity,  the  screening  and
monitoring  of  renal  lesions  is  indicated  in  all  patients
with  TSC.  The  initial  renal  evaluation  should  make  it
possible  to  advise  the  family  and  the  patient  and  to
plan  the  follow-up  and  treatment  (type  of  imaging,
frequency,  prophylactic  treatment).
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What type of monitoring should there be
before the age of 20?
Kidney  damage  caused  by  TSC  develops  mainly  before  20
years  of  age.  In  41  patients,  its  prevalence  was  19%  before
7  years  of  age,  33%  between  8  and  16  years  of  age  and  62%
after  that  [21]. In  60  children,  the  rate  of  kidney  damage
went  from  55%  at  the  beginning  of  monitoring  (mean  age,  6.9
years)  to  80%  at  the  end  of  the  study  (mean  age,  10.5  years)
[9].  The  median  age  of  detection  for  the  ﬁrst  abnormality
was  7.2  to  11.1  years  [9,10,20,21]. Cysts  can  exist  starting
from  birth,  and  AMLs  can  appear  during  the  ﬁrst  2  years  of
life  [9,20]. The  kidney  damage  appears  to  be  constituted  at
the  end  of  adolescence  [9,21], with  a  few  observations  of
abnormalities  that  appeared  after  20  years  of  age  [10,21].  In
these  cases,  the  kidney  damage  was  detected  by  ultrasound,
which  is  less  sensitive  than  a  CT  scan.  Certain  patients  could
thus  have  moderate  abnormalities  that  were  not  detected
before  20  years  of  age.
AMLs  grow  in  the  second  decade  of  life  [9,10,20,21]  with
growth  that  can  reach  more  than  4  cm  per  year  [9,10]. Bleed-
ing  complications  remain  exceptional  before  20  years  of  age
[10,21].
The  course  of  the  cysts  is  variable:  disappearance  [9]  or
progression  in  size  and  in  number  [4,20]. Simple  cysts  that
are  not  very  numerous  and  not  very  progressive  should  be
differentiated  from  RPC-related  cysts,  which  are  numerous,
voluminous,  bilateral  and  precocious  [21].The  monitoring  protocols  in  the  literature  are  variable
(Table  1).  They  prefer  ultrasound  (less  expensive  and  non-
radiating)  in  patients  under  20  years  of  age,  and  they  have
Table  1  Patient  monitoring  suggestions  in  the  literature.
Author Institution  
Cook,  1996  [5] Saint-James  University  Hospital,
Leeds,  UK
University  Hospital  of  Wales,  UK
Ewalt,  1998  [9] University  of  Texas,  USA
Bradshaw,  1998  [38] Scottish  collaborative  project
Casper,  2002  [20]  Children’s  Hospital  Medical  Cent
Cincinnati,  Ohio,  USA
Castagnetti,  2007  [21] University  of  Padua,  Italy
TSC: tuberous sclerosis complex; AML: angiomyolipomas.recommendations  227
elatively  spaced-out  follow-up  (rareness  of  complications
n  this  age  bracket)  [5,20,21,37,38].
RECOMMENDATION  2:  SCREENING  AND  MONITORING
DURING  THE  FIRST  TWO  DECADES  OF  LIFE
2a An  abdominal  ultrasound  should  be  performed  as
soon  as  the  TSC  is  diagnosed.  It  should  be  completed
with  an  evaluation  of  kidney  function  (serum
creatinine  level)  if  the  ultrasound  is  abnormal.
2b  This  evaluation  should  be  repeated  every  3  to  5
years  if  it  is  normal  and  every  2  to  3  years  if  the
ultrasound  only  demonstrates  a  few  cysts  or  AMLs
of  less  than  4  cm.
2c  If  there  are  many  voluminous  bilateral  cysts,
associated  polycystosis  should  be  suspected.  Due  to
the  risk  of  rapid  progression  towards  terminal  renal
insufﬁciency  (second  or  third  decade  of  life),  renal
function  and  blood  pressure  should  be  monitored
every  12  months  and  the  patient  should  be  oriented
towards  a  nephrology  consultation.
2d The  onset  of  symptoms  that  are  compatible  with
a  renal  complication  (pain  in  the  side,  abdominal
heaviness,  haematuria,  state  of  shock),  the  rapid
growth  of  an  AML,  AML  size  of  greater  than  4  cm  or
the  development  of  a  suspicious  tissue  mass  seen
on  the  ultrasound  should  result  in  a  CT  scan  or  MRI.Proposed  monitoring
Abdominal  ultrasound  upon  diagnosis  of  TSC
Abdominal  ultrasound  every  5  years  if  negative
Abdominal  ultrasound  ever  1  to  2  years  if  AML
CT  scan  or  MRI  if  there  is  a  doubt  about  a
malignant  lesion
Ultrasound  every  2  to  3  years  before  puberty
Annual  ultrasound  after  this
Ultrasound  at  5  years  of  age
Ultrasound  every  5  years  if  negative
Ultrasound  and  serum  creatinine  level  every  2
to  3  years  if  renal  abnormalities  of  <  4  cm
Ultrasound  every  year  if  renal  abnormalities  >  4
years
re, No monitoring  via  imaging  during  the  ﬁrst
decade  of  life
Ultrasound  every  2  years  if  negative  or  if
lesions  are  small
Ultrasound  every  6  to  12  months  if  lesions  are
voluminous
CT  scan  or  MRI  only  if  there  are  symptoms
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hat kind of monitoring in adulthood?
fter  the  age  of  20,  the  growth  of  AMLs  slows  down.  We  do
ot  know  if  there  is  an  age  beyond  which  growth  is  zero  [10].
ong-term  monitoring  of  renal  abnormalities  has  not  been
tudied.  Adults  with  kidney  damage  have  three  major  risks:
aemorrhagic  rupture  of  an  AML  (most  often  after  20  years
f  age),  CRI  due  to  progressive  destruction  of  the  kidneys  by
MLs  (RPC  is  generally  diagnosed  before  20  years  of  age)  or
 malignant  tumour.
These  risks  justify,  in  some  cases,  the  need  for  monitor-
ng  using  imaging  [10,16].  The  ultrasound  is  not  ideal,  as
t  does  not  assess  the  size  of  the  AMLs  well,  especially  if
hey  are  coalescent.  CT  scan  and  MRI  have  better  precision
39,40].  CT  scan,  thanks  to  its  short  acquisition  time,  can
ake  it  possible  to  avoid  general  anaesthesia,  but  repeated
se  exposes  the  patient  to  high  doses  of  radiation  [40,41].
on-radiating  MRI  is  an  alternative  for  monitoring,  but  its
uration  can  make  general  anaesthesia  necessary.
RECOMMENDATION  3:  MONITORING  MODALITIES  IN
ADULTS
3a Long-term  monitoring  of  kidney  damage  is
recommended  to  follow-up  the  progression  of  AMLs
and  to  make  sure  that  malignant  tumours  and  renal
insufﬁciency  do  not  occur.  The  imaging  monitoring
in  adults  should  be  based  on  CT  scans  or  MRIs
(preferably  MRIs  to  reduce  patient  exposure  to
radiation)  rather  than  ultrasounds.
3b  In  asymptomatic  patients  with  at  least  one  AML  of
more  than  4  cm,  assay  of  serum  creatinine  and  a  CT
scan  or  MRI  examination  should  be  carried  out  every
2  years.  This  frequency  should  be  adjusted  based  on
the  progression  of  the  AMLs.
3c  In  asymptomatic  patients  who  do  not  have  renal
abnormalities  or  AML  of  less  than  4  cm,  the
morphological  monitoring  (CT  scan  or  MRI)  and
kidney  function  monitoring  can  be  gradually
spaced-out,  especially  if  the  results  are  stable.
3d  The  onset  of  symptoms  that  are  compatible  with
a  renal  complication  (pain  in  the  side,  abdominal
heaviness,  haematuria,  state  of  shock)  should  result
in  a  CT  scan  or  MRI  examination  immediately.
ow to distinguish between an
ngiomyolipomas  and a malignant tumour. Are
here indications for percutaneous biopsy of
idney masses?
n  ultrasounds,  AMLs  are  homogeneous  and  hyperechogenic
42—45]  with  a  non-pathognomonic  appearance,  since  up  to
%  of  kidney  cancers  are  hyperechogenic  [45]. AML  is,  with
 few  rare  exceptions  [46—49], the  only  kidney  tumour  that
ontains  a  fatty  contingent.  CT  scan  thus  conﬁrms  the  diag-
osis  by  showing  the  presence  of  fat  in  the  tumour  (areas  of
egative  density)  [43,50,51]. MRI  is  not  used  very  commonly
n  the  positive  diagnosis  of  renal  AMLs.
s
T
a
iO.  Rouvière  et  al.
Certain  AMLs  have  a  very  minority  fatty  contingent  (<  10%
52]),  which  is  undetectable  on  the  CT  scan.  These  ‘‘fat
oor  AMLs’’  account  for  2.5  to  6.9%  of  operated  kidney
umours  [53—55]. Ultrasound  is  not  informative,  as  fat  poor
MLs  are  generally  iso-  or  hypoechogenic  [56—58]. Up  to
9%  of  AMLs  associated  with  TSC  appear  not  to  have  a  fatty
omponent  that  can  be  visualised  using  CT  scan  [59]. There-
ore,  we  cannot  suggest  biopsy  for  all  renal  masses  that
o  not  contain  fat  of  patients  with  TSC.  The  main  crite-
ia  for  suspecting  a  cancer  are  rapid  growth,  calciﬁcations,
r  central  necrosis  [60]. The  interpretation  of  the  speed  of
rowth  must  take  into  account  the  circumstances  where  the
MLs  progress:  adolescence,  pregnancy  or  oestro-progestin
reatment  [9,10,14,20,61—63]. In  12  patients  (206  renal
asses)  monitored  for  a  duration  of  2  to  8  years  (median,
 years),  three  fast-growing  masses  (>  0.5  cm/year)  were
eported,  including  a  renal  cell  carcinoma  conﬁrmed  by
iopsy  [59]. As  the  AMLs  associated  with  TSC  are  gener-
lly  multiple  and  bilateral,  the  discovery  of  a  single  renal
ass  without  a  fatty  contingent  can  also  be  a  cause  for
iopsy.
RECOMMENDATION  4:  INDICATIONS  FOR  THE
BIOPSY  OF  RENAL  MASSES
4a Given  the  high  proportion  of  fat  poor  AMLs
associated  with  TSC,  the  absence  of  fat  in  a  renal
mass  is  not  a  sufﬁcient  criterion  for  proposing  a
biopsy.
4b  A  biopsy  can  be  considered  to  rule  out  a  malignant
tumour  if  there  are  calciﬁcations,  central  necrosis
or  rapid  growth  of  a  mass  without  a  fatty
contingent,  or  if  there  is  a  single  renal  mass  without
a  fatty  contingent.
hould pulmonary lymphangioleiomyomatosis
ystematically  be screened for  in patients
ith renal damage caused by tuberous
clerosis complex?
ulmonary  lymphangioleiomyomatosis  (LAM)  is  a  rare  dis-
ase  that  can  be  isolated  or  associated  with  TSC.  It
oncerns  almost  exclusively  adult  women  and  combines
neumothorax,  chylothorax  and  dyspnoea  that  can  lead  to
erminal  respiratory  insufﬁciency.  Chylous  ascites  and  lym-
hangiomas  can  also  be  encountered  [64,65].
In  388  patients  (of  both  sexes)  with  TSC,  9  (2.3%,  all
omen)  had  symptomatic  LAM  [66]. Three  studies  have
esearched  the  existence  of  LAM  using  chest  CT  scans  in
atients  with  TSC:  26  to  39%  of  these  patients  had  pulmonary
ysts  that  were  compatible  with  asymptomatic  LAM  [67—69].
AM  is  commonly  associated  with  renal  AMLs  (32  to  53%)
65,70].  The  incidence  of  LAM  in  patients  with  bilateral  AMLs
as  been  estimated  to  be  between  6.4%  and  24.8%  [64]. The
uropean  Respiratory  Society  has  recommended  systematic
creening  for  LAM  using  a  chest  CT  scan  in  all  women  with
SC  at  18  years  of  age,  then,  if  this  ﬁrst  CT  scan  is  negative,
t  30  to  40  years  of  age.  The  chest  CT  scan  is  only  indicated
n  men  if  they  have  respiratory  symptoms  [64].
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at  5  and  10  years  [73]. Embolisation,  therefore,  appears  toKidney  damage  due  to  tuberous  sclerosis  complex:  Managem
RECOMMENDATION  5:  CHEST  CT  SCAN  TO  SCREEN
FOR  RELATED  LAM
5a  A  chest  CT  scan  without  injection  to  screen  for
pulmonary  LAM  should  be  systematically  carried
out  in  all  women  with  TSC  without  respiratory
symptoms  (with  or  without  kidney  damage)  at  18
years  of  age,  then,  if  negative,  at  30  to  40  years  of
age.
5b Systematic  screening  for  LAM  is  not  necessary  in
men  with  TSC  (even  with  kidney  damage)  without
respiratory  symptoms.
5c  The  onset  of  respiratory  symptoms  (unexplained
dyspnoea,  pneumothorax)  should  result  in  a  chest
CT  scan  regardless  of  the  sex  of  the  patient.
What therapeutic strategy should be adopted
in case of spontaneous rupture of an
angiomyolipomas?
Spontaneous  rupture  of  an  AML  ranges  from  a  limited
and  resolving  perirenal  haematoma  to  fatal  bleeding.  Con-
servative  treatment  (intensive  care  and  transfusions)  can
prevent  renal  procedures  in  the  long-term  [71], but  in  prin-
ciple,  a  spontaneous  rupture  requires  treatment  to  avoid
putting  the  patient’s  life  in  danger  and  to  prevent  a  relapse
[5,14,33,37,72—82].
Conservative  surgery,  which  is  difﬁcult  in  an  emergency
situation,  often  ends  up  in  a  haemostasis  nephrectomy.  Per-
cutaneous  embolisation  can  treat  the  origin  of  the  bleeding
with  a  low  complication  rate  (Table  2).  Bleeding  relapses
after  emergency  embolisation  can  occur  (0  to  60%  of  cases)
in  a  time  period  of  up  to  3  years.  They  are  generally  treated
with  success  via  a  second  embolisation  [72—74,78,83]. Use
of  surgery  is  rare  when  embolisation  is  used  as  ﬁrst-line
treatment  (Table  2).
RECOMMENDATION  6:  TREATMENT  OF  A
SPONTANEOUS  HAEMORRHAGIC  RUPTURE  OF  AN
AML
6a  Patients  should  be  informed  of  the  risk  and  clinical
signs  of  a  haemorrhagic  rupture  of  an  AML  (acute
pain  in  the  side,  state  of  shock)  and  the  hospital
centres  that  are  able  to  treat  these  acute  ruptures
that  are  near  their  homes  should  be  identiﬁed.
6b  Embolisation  should  be  proposed  as  ﬁrst-line
treatment  in  case  of  spontaneous  haemorrhagic
rupture  of  an  AML.
6c  Surgery  should  only  be  used  in  cases  where
embolisation  is  not  available  in  an  emergency
context  or  not  technically  possible.  It  should  be  as
conservative  as  possible.
a
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hould angiomyolipomas associated with
uberous sclerosis complex be treated
reventively? If  yes, based on what criteria
nd using what technique?
poradic  AMLs  of  more  than  40  mm  have  more  risks  of
omplications.  Preventive  treatment  with  embolisation  or
urgery  is  recommended  [14,76,84—86].
AMLs  associated  with  TSC  progress  more  quickly  [15]
nd  appear  to  become  complicated  more  frequently
15,72,74,87].  A  threshold  of  35  mm  has  thus  been  suggested
or  their  prophylactic  treatment  [88]. However,  the  fre-
uency  of  their  complications  could  simply  be  due  to  their
arger  mean  diameter  and  their  larger  number  per  patient.
In  two  studies,  the  mean  size  of  the  AMLs  (sporadic  or
ssociated  with  TSC)  embolised  for  bleeding  was  85  mm  (35
o  200  mm)  and  78  mm  (45  to  180  mm)  [75,89]  and  the  indi-
idual  bleeding  risk  remains  moderate,  even  in  patients  with
SC  (approximately  6%)  [10]. Some  have  thus  suggested  a
hreshold  of  80  to  100  mm  for  the  prophylactic  treatment  of
MLs  associated  with  TSC  [33,85].
The  size  alone,  however,  does  not  appreciate  the  risk  of
leeding  very  well.  The  relative  importance  of  the  vascular
nd  fatty  contingents  and  the  existence  of  intra-tumoural
icro-aneurisms  of  greater  than  5  mm  could  also  be  risk
actors  [90,91].  Unfortunately,  the  detection  of  micro-
neurisms  requires  arteriography.
Surgery  or  embolisation  can  be  used  for  the  preventive
reatment  of  AMLs.
Surgical  removal  of  sporadic  AMLs  has  a  low  risk  of
omplications  and  relapse  (Table  3)  [92—96]. However,  par-
ial  surgery  is  clearly  more  complicated  in  TSC  due  to  the
ultiplicity  of  AMLs.
Embolisation  appears  to  be  the  easiest  solution  for  AMLs
n  patients  with  TSC,  with  few  complications  [Table  2]
33,37,73—75,77,80—83,89,97,98]. Six  to  100%  of  patients
ave  a  ‘‘post-embolisation  syndrome’’  with  lumbar  pain  and
ever,  which  can  be  controlled  with  a  non-steroidal  anti-
nﬂammatory  treatment  [73]  or  short-term  corticosteroid
reatment  [99]. Embolisation  causes  a  reduction  in  the  diam-
ter  of  the  treated  AML,  the  importance  of  which  (20  to
0%)  depends  on  the  proportion  of  vascular  and  fatty  contin-
ents.  The  fatty  part  of  the  AML  does  not  regress  very  much
fter  embolisation  [37,75,81,82,87,89,90,98]  but  there  are
owever  some  exceptions  [100]. The  reduction  in  size  is
ccentuated  over  time:  in  the  Takemayashi  et  al.  series,  it
as  29.4%,  45.7%  and  59.3%  at  3,  6  and  12  months,  respec-
ively  [101]. Embolisation  can  be  repeated  during  monitoring
n  6  to  50%  of  patients  (Table  2).  In  a  series  of  44  treated
idneys,  survival  without  re-embolisation  was  71%  at  5  years
nd  37%  at  10  years,  and  survival  without  surgery  was  94%void  surgery,  but  at  the  price  of  repeated  sessions.  The  per-
entage  of  spontaneous  bleeding  after  embolisation  is  low
0  to  5.3%,  Table  2).
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Table  2  Results  of  the  main  series  of  embolisation  of  angiomyolipomas.
Author  Number
of  Pts
%  Pts
TSC
Embolic  agent  %  acute
bleed.
Mean  size
(mm)
%
failure
Post-embol.
syndrome  (%)
Major
complications
(%)
% Re-
embol.
% post-
embol.
bleed.
Post-
embol.
surgery
Mean
follow-up
(months)
Han,  1997  [98]  14  7.1  Alcohol  +  lipiodol,
alcohol  alone,
coils  +
microparticles
+ gel  foam
0 110  (40—350)  0  100  Abscess
(drainage,  n  =  1)
14.3  0  7.1  >  12
months  in
12  pts
Harabayashi,
2004  [33]
12  100  Alcohol  +  coils  0  ND  0  ND  Renal  atrophy
(n  =  1)
50 0  0  60
(12—170)
Ewalt,  2005
[37]
16  100  Microparticles  18.8  ND  (40—210)  0  68.8  Pneumonia
(n  =  1)
0 0  0  ND
Khotary,  2005
[74]
19  52.6  Alcohol  +  lipiodol  36.8  ND  0  100  0  31.6a 5.3  0  51.5
(6—132)
William,  2006
[82]
16  100  Microparticles
±  coils
37.5  NDb 0  6.2  0  0  0  0  40  (6—62)
Dabbeche,
2006  [75]
37  10.8c Microparticles  ±
coils  ±  Alcohol
43.2  78
(45—180)/53
(40—110)d
8.1  16.2  Arterial  breach
(nephrectomy,
n  =  1),  arterial
dissection
(stent,  n  =  1)
10.8  2.7e 32.4
(50/21.1)d
21
Lenton,  2008
[80]
17  70  Microparticles
(350—500  )  ±  coils
43.5  ND  0  30.4  0%  17.6  4.4  0  ND
Chick,  2009
[97]
34  26  Alcohol  +  lipiodol  0  119  (29—244)  0  32.4  Renal  infarction
(n  =  1)
5.9 0  8.8  44
(12—116)
Sooriakumaran,
2009  [83]
19  26.3  ND  31.6  ND  0  15.8  Abscess  (n  =  1),
renal  atrophy
(n  =  1),
refractory
hypertension
(n  =  1)
36.8 0  5.3  ND
Lee,  2009  [81]  11  36.4  Gel  foam  ±  coils,
alcohol  +  lipiodol
36.4  85  (45—128)  18.2  63.7  Abscess
(drainage,  n  =  1)
9.1  0  9.1  28.2
(8.8—84.5)
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Table  2 (Continued)
Author Number
of  Pts
%  Pts
TSC
Embolic  agent %  acute
bleed.
Mean  size
(mm)
%
failure
Post-embol.
syndrome  (%)
Major
complications
(%)
% Re-
embol.
% post-
embol.
bleed.
Post-
embol.
surgery
Mean
follow-up
(months)
Ramon,  2009
[73]
41 19.5  Alcohol  +
microparticles
(45—50  )  ±  coils
24.4 103  (25—200)  0 12.5 0 36.6 0 7.3 57
Chan,  2011
[77]
27 3.7  Coils,
alcohol  +  lipiodol,
microparticles
(150—250  )
53.6 109  (4—30)  7.1 40.7 0 14.8  0 14.8 85
(15—242)
Villalta,  2011
[89]
48 34.8  Microparticles
(40—1200  )
44.7/7.1f 78
(35—320)/85
(35—200)f
ND  6.2  Acute  dyspnoea
(n  =  3),  abscess
(nephrectomy,
n =  1),  common
femoral  lesion
(n  =  1)
29.2 0  2.1  20/21f
Only the series of more than 10 patients were taken into account. Bleed.: bleeding; Pts: patients; embol.: embolisation; TSC: tuberous sclerosis complex.
a Only in TSC patients.
b Mean volume: 315 cc (27.8 to 814.4 cc).
c Plus two patients with pure LAM.
d Emergency embolisation/planned embolisations.
e Twice.
f TSC patients/non TSC patients.
2 O.  Rouvière  et  al.
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RECOMMENDATION  8:  EMBOLISATION  TECHNIQUE
8a  Embolisation  must  concern  both  the  tumour  bed
and  the  proximal  trunks  upstream  of  the  micro-
aneurysms.
8b  If  microparticles  are  used,  their  size  must  be
greater  than  500    to  reduce  the  risk  of  intra-
pulmonary  passage.
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RECOMMENDATION  7:  PREVENTIVE  TREATMENT  OF
AMLS
7a  Any  preventive  treatment  of  an  AML  must  be
validated  in  a  multidisciplinary  manner  and
discussed  with  the  patient  and  his  or  her  family,  who
must  be  informed  of  the  potential  complications  of
treatment  and  the  uncertainties  with  regard  to  the
prediction  of  the  bleeding  risk.
7b A  preventive  treatment  is  recommended  for
asymptomatic  AMLs  cumulating  bleeding  risk
factors:  size  greater  than  80  mm,  predominant
vascular  contingent,  presence  of  micro-aneurisms.
7c  A  preventive  treatment  can  be  considered  for  AMLs
that  are  greater  than  40  mm  after  informed  consent
of  the  patient  and  his  or  her  family,  especially  if
there  are  other  risk  factors  (risks  of  lumbar  trauma,
intention  to  become  pregnant,  anti-coagulant
treatment,  distance  from  a  healthcare  centre,
etc.).  It  must  be  validated  in  a  multidisciplinary
manner  (7a).
7d  When  preventive  treatment  of  an  asymptomatic
AML  is  decided,  embolisation  must  be  suggested  as
ﬁrst-line  treatment.
7e  Embolised  AMLs  must  be  checked  by  CT  scan  (or  MRI)
at  1  and  2  years.  If  the  result  is  good,  monitoring
every  2  years  is  sufﬁcient  from  that  point  on  (3b).
7f  When  there  is  an  indication  for  preventive
treatment,  surgery  can  be  an  option  if  there  is
failure  of  embolisation  or  in  certain  particular
cases  (isolated  AML,  exo-renal  location,  predictable
difﬁculties  for  post-embolisation  follow-up,  etc.).
hat is  the best technique for embolisation?
here  is  no  consensus  regarding  the  embolic  agent(s)  to  be
sed  (Table  2).  Proximal  embolisation  alone  (for  example,
sing  coils)  exposes  the  patient  to  the  risk  of  revascularisa-
ion  via  collateral  branches.  Embolisation  of  the  tumour  bed
lone  (for  example,  using  microparticles)  leaves  the  micro-
neurisms  to  be  treated  and  exposes  the  patient  to  their
upture  due  to  excessive  pressure  [74,80].  Double  embolisa-
ion  of  the  tumour  bed  and  the  proximal  trunks  is  therefore
equired.
The  small  size  microparticles  (<  150  )  seem  less  effec-
ive  than  the  large  ones  (>  150  ),  with  a  risk  of
e-embolisation  that  is  six  times  higher  [89]. Three  cases
f  respiratory  distress  with  pulmonary  hypertension  after
mbolisation  with  microparticles  less  than  500    [89]  and
ve  cases  of  fatal  pulmonary  embolism  after  embolisation
f  hepatic  masses  with  microparticles  of  40  to  120    have
een  described  [102—104].  It,  therefore,  seems  prudent  to
se  microparticles  that  are  greater  than  500    for  which  no
omplications  of  this  type  have  been  reported.
Ethanol,  which  is  only  for  use  by  teams  that  have  been
rained  in  handling  it,  can  be  used.  The  dose  of  0.25  mL/kg
ust  not  be  exceeded  due  to  the  cardio-respiratory  risk.
nyx  has  also  been  used  [105], but  it  is  too  early  to  draw
ny  conclusions.
T
[
p8c Ethanol  is  effective  but  must  only  be  used  by  teams
that  have  been  trained  in  its  endovascular  use.
hat advice should be given to a woman with
ngiomyolipomas who would like to become
regnant or who would like a contraceptive
reatment?
regnant  patients  should  know  that  the  child  has  a  50%  risk
f  being  a  carrier  of  the  disease.
Pregnancy  and  oestro-progestin  contraception  are  risk
actors  for  the  progression  and/or  spontaneous  rupture  of
MLs  [61,62,106—112].
Patients  with  a related  LAM  have  an  increased  risk  of
neumothorax  and  chylothorax  in  case  of  pregnancy  and
dministration  of  oestrogen  can  accelerate  the  degenera-
ion  of  their  respiratory  function  [64].
RECOMMENDATION  9:  ADVICE  FOR  PATIENTS  WHO
WOULD  LIKE  TO  BECOME  PREGNANT  OR  WHO
WOULD  LIKE  AN  OESTRO-PROGESTIN  TREATMENT
9a Patients  with  TSC  who  would  like  to  become
pregnant  must  have  a  genetic  consultation  before
any  conception.
9b Patients  with  TSC  who  would  like  to  become
pregnant  must  be  informed  of  the  risks  inherent
to  a  possible  pregnancy:  AML  rupture  and
(in  case  of  related  pulmonary  LAM)  risks  of
pneumothorax,  chylothorax  and  progression  of
respiratory  insufﬁciency.
9c Patients  with  TSC  who  have  renal  AMLs  (and/or
pulmonary  LAM)  should  avoid  oestrogenic
treatments  (oestro-progestin  pill,  oestrogen
replacement  treatment)  due  to  the  risk  of  rupture
of  renal  AMLs  and  progression  of  the  pulmonary
LAM.
9d  A  preventive  treatment  can  be  considered  for
AMLs  greater  than  40  mm  after  informed  consent
of  the  patient  and  of  his  or  her  family,  and
multidisciplinary  discussion,  if  the  patient  would
like  to  become  pregnant  (7c).
s there a role for treatment with mTOR
nhibitors?wo  prospective  non-randomised  studies  used  sirolimus
113,114].  One  randomised  study  (everolimus  versus
lacebo)  is  ongoing.
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Table  3 Results  of  the  main  series  of  surgery  of  angiomyolipomas.
Number  of  Pts TSC  Pts  (%) Mean  size
(mm)
Nephrectomy
type
Complications Re-procedures  (except
ureteral  stent
placement)
Mean follow-up
(months)
Fazeli-Matin,
1998  [95]
27 7.4  74  (15—260)  Partial Signiﬁcant  increase
in  serum  creatinine
levels  (only  if  single
kidney,  n  =  15)
Urinary  ﬁstula  (n  =  3)
Postop.  infections
(n  =  3)
Adrenal  insufﬁciency
(n  =  1)
0 39 (median)  (2—177)
Heidenreich,
2002  [96]
28 3.6  55  (median)
(25—150)
Partial Urinary  ﬁstula  (n  =  3) 1  (closure  of  urinary
ﬁstula)
58  (median)  (3—114)
Yip,  2000
[92]
23 13 123  (15—300)  Partial  (n  =  16)
Total  (n  =  7)
Minor  stroke  (n  =  1)
Arteriovenous  ﬁstula
(embolisation,  n =  1)
0  26  (1—80)
Boorijian,
2007  [93]
58  0  39  (median)
(8—125)
Partial  Urinary  ﬁstula  (n  =  3)
Postop.  abscess
(n  =  1)
Postop.  ileus  (n  =  5)
Pneumothorax
(n  =  1)
Postop.  bleeding
(n  =  1)
Acute  renal
insufﬁciency  (n  =  1)
1 (embolisation  of
postop.  bleeding)
72 (median)
(12—372)
De  Luca,
1999  [94]
20  10  81
(25—170)/20
(3—100)a
Partial  (n  =  14)
Total  (n  =  6)
ND
TSC: tuberous sclerosis complex; Pts: patients; Postop.: postoperative.
a Symptomatic/asymptomatic.
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The  studies  with  sirolimus  showed  a  regression  of  the  vol-
me  of  the  AMLs  under  treatment.  In  the  ﬁrst  study,  at  12
onths,  the  volume  of  the  AMLs  was  53.2  ±  26.6%  of  the
nitial  volume.  But  the  size  of  the  AMLs  increased  again
fter  discontinuation  of  treatment  and  their  volume  after
2  months  of  discontinuation  was  85.9  ±  28.5%  of  the  ini-
ial  volume  [113]. In  the  second  study,  the  response  rate
RECIST  criteria)  was  80%  for  patients  who  remained  in  the
tudy  until  the  end  (8  out  of  10).  It  should  be  noted,  how-
ver,  that  ﬁve  AMLs  grew  during  treatment  in  two  patients
ho  withdrew  from  the  study  early  [114].
Serious  complications  under  treatment  (stomatitis,
iarrhoea  and  various  infections  [particularly  pulmonary
nfections])  are  numerous:  six  out  of  25  patients  in  the  ﬁrst
tudy,  seven  out  of  16  (including  one  death)  in  the  second
tudy  and  one  case  of  retroperitoneal  bleeding  [113].
Treatment  with  mTOR  inhibitors  can  have  beneﬁcial
ffects  on  the  respiratory  function  of  patients  with  LAM
y  improving  [113]  or  slowing  down  its  deterioration
114,115].  It  may  improve  certain  cognitive  functions
114].
In  all,  treatments  with  mTOR  inhibitors  can  signiﬁ-
antly  reduce  the  volume  of  most  AMLs  (but  not  of  all
MLs).  Their  effect  is  reversible  upon  treatment  discontin-
ation.  It  has  not  yet  been  proven  that  the  decrease  in
he  size  of  the  AMLs  is  accompanied  by  a  decrease  in  the
leeding  risk.  The  beneﬁt/risk  ratio  of  mTOR  inhibitors  is
ot  sufﬁciently  favourable  to  use  them  as  ﬁrst-line  treat-
ent.
RECOMMENDATION  10:  ROLE  OF  TREATMENT  WITH
MTOR  INHIBITORS
10a  Due  to  their  potential  adverse  effects,  mTOR
inhibitors  should  only  be  prescribed  by  specialised
teams  and  if  possible  within  the  framework  of
clinical  studies.  The  creation  of  a  national  registry
listing  patients  treated  outside  of  a  protocol  is
encouraged.
10b  mTOR  inhibitors  must  not  be  used  as  ﬁrst-line
treatment  in  the  treatment  of  renal  AMLs.
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